Endocytoscopy for histological evaluation of inflammation in ulcerative colitis

doi:10.3748/wjg.119611

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 32, Issue 37

This Article

(4)

(0)

(1)

(42)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastroenterol. Oct 7, 2026; 32(37): 119611
Published online Oct 7, 2026. doi: 10.3748/wjg.119611

Table 4 Comparison of baseline characteristics between endoscopic scoring active and inactive groups, n (%)

Patient characteristics	Total (n = 72)	ECSS-active (n = 23)	ECSS-inactive (n = 49)	P value	P value (Bonferroni)
Sex
Female	36 (50.00)	11 (47.83)	25 (51.02)	0.800	-
Male	36 (50.00)	12 (52.17)	24 (48.98)	0.800	-
Age, median (range), years	38.3 ± 14.7	36.05 ± 3.03	41.70 ± 14.7	0.128	-
Disease duration, median (range), years	38.3±14.7	30 (18.0, 51.0)	5 (18.0, 78.0)	0.108	-
Extent of colitis				0.029	-
Pancolitis (E3)	25 (34.72)	13 (56.52)	12 (24.49)		0.021 (E3 vs E2)
Left-sided colitis (E2)	28 (38.89)	6 (26.09)	22 (44.90)		1.000 (E2 vs E1)
Proctitis (E1)	19 (26.39)	4 (17.39)	15 (30.61)		0.037 (E1 vs E3)
MES				0.002	-
Mayo 0	55 (76.39)	12 (52.17)	43 (87.76)		0.048 (Mayo 0 vs Mayo 1)
Mayo 1	9 (12.50)	5 (21.74)	4 (8.16)		0.620 (Mayo 1 vs Mayo 2)
Mayo 2	8 (11.11)	6 (26.09)	2 (4.08)		0.005 (Mayo 2 vs Mayo 0)
Mayo 3	0	0	0	-	-
Use of medication for UC
Biological therapy	21 (29.17)	9 (39.13)	12 (24.49)	1.000	-
Infliximab	5 (6.94)	2 (8.70)	3 (17.39)
Vedolizumab	14 (19.44)	6 (26.09)	8 (17.39)
Ustekinumab	2 (2.78)	1 (4.35)	1 (17.39)
Non-biological therapy	49 (68.05)	23 (100)	26 (53.06)	0.703	-
Mesalazine	47 (65.28)	23 (100)	24 (48.98)
Steroids	4 (5.56)	3 (13.04)	1 (4.35)
Immunosuppressants	3 (4.17)	2 (8.70)	1 (4.35)
CRP mean (range) mg/dL	1.9 (0.9, 6.9)	5.17 (0.78, 20.27)	1.44 (0.79, 3.33)	0.042	-

ECSS: Endoscopic scoring; MES: Mayo endoscopy score; CRP: C-reactive protein; UC: Ulcerative colitis.

Full Size Table

Citation: Li M, Lou XY, Liu ZC, Peng B, Huang Y, Guo Q. Endocytoscopy for histological evaluation of inflammation in ulcerative colitis. World J Gastroenterol 2026; 32(37): 119611
URL: https://www.wjgnet.com/1007-9327/full/v32/i37/119611.htm
DOI: https://dx.doi.org/10.3748/wjg.119611

Li M, Lou XY, Liu ZC, Peng B, Huang Y, Guo Q. Endocytoscopy for histological evaluation of inflammation in ulcerative colitis. World J Gastroenterol 2026; 32(37): 119611 [DOI: 10.3748/wjg.119611]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.